Although further investigation is required to clarify the efficacy of this drug for tumors exhibiting CSC-like properties in the clinical setting, our study indicates that FTD-based treatment might lead to improved clinical outcomes for patients with tumours exhibiting high CD44 and CD133 expression. Here, CD44 is linked to neoplasm.